Erin K. Crane, MD, MPH
- Associate Professor, Obstetrics and Gynecology (Charlotte)

Erin K. Crane, MD, MPH
- Associate Professor, Obstetrics and Gynecology (Charlotte)
- Education
- MD, State University of New York Upstate Medical University, 2006
- State University of New York University at Albany, 2006
- Residency
- Obstetrics and Gynecology, University of Virginia School of Medicine
- Fellowship
- Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center
- Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center
- Board Certifications
- American Board of Obstetrics and Gynecology, Gynecologic Oncology
- American Board of Obstetrics and Gynecology, Obstetrics and Gynecology
- Positions
- Associate Professor, Obstetrics and Gynecology (Charlotte)
- Departments and Affiliations
- Obstetrics and Gynecology (Charlotte)
Research
- Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies. Levytska K, Naumann RW, Benfield MJ, Brown J, Casablanca Y, Lees B, Puechl AM, Crane EK. Gynecol Oncol Rep. 2025 Apr; 58:101727.
- Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Duska LR, Petroni GR, Thaker PH, Crane EK, Holman LL, Armstrong DK, Romano K, Scalici J. Cancer. 2025 Feb; 131(4):e35757.
- Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Gynecol Oncol. 2024 Nov; 190:283-290.
- Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial. Costales AB, Crane EK, Chambers L, Yao M, Chau D, Naumann WR, Debernardo R, Ricci S, Rose PG, Michener CM. Gynecol Oncol. 2024 Jun; 185:143-147.
- A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Int J Gynecol Cancer. 2023 Sep; 33(9):1458-1463.